{"id":"NCT01318122","sponsor":"Takeda","briefTitle":"Long-term Safety Study of Alogliptin Used in Combination With Thiazolidine in Participants With Type 2 Diabetes in Japan","officialTitle":"A Long-Term, Open-Label Extension Study to Investigate the Long-Term Safety of SYR-322 When Used in Combination With Thiazolidine in Subjects With Type 2 Diabetes in Japan","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2008-05","primaryCompletion":"2009-08","completion":"2009-08","firstPosted":"2011-03-18","resultsPosted":"2011-09-02","lastUpdate":"2012-02-03"},"enrollment":336,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Alogliptin and pioglitazone","otherNames":["SYR-322","Actos"]},{"type":"DRUG","name":"Alogliptin and pioglitazone","otherNames":["SYR-322","Actos"]}],"arms":[{"label":"Alogliptin 12.5 mg QD and Pioglitazone 15 or 30 mg QD","type":"ACTIVE_COMPARATOR"},{"label":"Alogliptin 25 mg QD and Pioglitazone 15 or 30 mg QD","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study was to evaluate the long-term safety and efficacy of alogliptin and Thiazolidine administered once daily (QD) for 40 consecutive weeks in participants who completed a phase 2/3 Thiazolidine add on study.","primaryOutcome":{"measure":"Number of Participants With Adverse Events.","timeFrame":"52 Weeks.","effectByArm":[{"arm":"Alogliptin 12.5 mg QD and Pioglitazone 15 or 30 mg QD","deltaMin":14,"sd":null},{"arm":"Alogliptin 25 mg QD and Pioglitazone 15 or 30 mg QD","deltaMin":11,"sd":null}],"pValues":[]},"eligibility":{"minAge":"33 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":166},"commonTop":["Nasopharyngitis","Blood creatine phosphokinase increased","Upper respiratory tract inflammation","Back pain","Arthralgia"]}}